FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4242969382> ?p ?o ?g. }

• W4242969382 endingPage "6" @default.
• W4242969382 startingPage "PD1" @default.
• W4242969382 abstract "Abstract Background: Metastatic triple-negative breast cancer (TNBC) is associated with a poor prognosis and has no targeted therapy options. Programmed death-ligand 1 (PD-L1) expression is more prevalent in TNBC than in other breast cancer subtypes. PD-L1 may protect cancer cells from immune-mediated destruction by binding to its receptors PD-1 and B7.1. MPDL3280A, a human anti-PD-L1 monoclonal antibody with an engineered Fc-domain designed for optimized efficacy and safety, blocks PD-L1 activity and restores tumor-specific T-cell immunity. Methods: This multicenter Phase I study selectively enrolled a cohort of patients with PD-L1-positive metastatic TNBC. PD-L1 positivity was centrally evaluated based on the PD-L1 immunohistochemistry (IHC) status of tumor-infiltrating immune cells (ICs). Eligible patients received MPDL3280A 15 or 20 mg/kg IV every 3 weeks for up to 1 year. The objective response rate (ORR) was assessed by RECIST v1.1. MPDL3280A immune correlates were evaluated for tumor and circulating biomarkers. The clinical data cutoff was January 1, 2014. Results: Twelve patients were treated with MPDL3280A and evaluable for safety. Patients had ECOG PS 0-1 (33% ECOG PS 1), and the median age was 55 years (range, 29-72 years). All 4 patients (33%) with visceral metastases had liver metastases, and 1 patient (8%) had bone metastases. 92% of patients received ≥ 2 prior therapies. Prior chemotherapies included anthracycline (92%), taxane (75%) and platinum (42%). Grade 3-4 treatment-related adverse events (AEs) occurred in 8% of patients (1 event of Grade 3 adrenal insufficiency). One patient had an immune-related AE (Grade 2 pyrexia). No treatment-related deaths were observed. Nine patients were dosed by November 16, 2013 and evaluable for efficacy. The ORR was 33%, including 1 CR and 2 PRs. Responders included patients with visceral metastases at baseline. At the time of the clinical data cut-off, all responses occurred within 6 weeks of the first dosing of MPDL3280A, and all of the responses were ongoing. The median duration of response had not been reached. One patient achieved stable disease as best response. Two additional patients had tumor shrinkage (-43% and -44% change in target lesions, respectively) but were not counted as RECIST responders due to the appearance of new lesions, which is likely attributable to pseudoprogression. Preliminary pharmacodynamic biomarkers related to MPDL3280A activity, including circulating plasma markers and tumor immunomonitoring with CD8 IHC, will be presented along with updated clinical data. Conclusions: MPDL3280A treatment was well tolerated and was associated with objective clinical activity in patients with pretreated metastatic TNBC. Further evaluation of the safety and clinical activity of MPDL3280A in both PD-L1-positive and PD-L1-negative metastatic TNBC is ongoing. Clinical trial information: NCT01375842. Citation Format: Leisha A Emens, Fadi S Braiteh, Philippe Cassier, Jean-Pierre DeLord, Joseph Paul Eder, Xiaodong Shen, Yuanyuan Xiao, Yan Wang, Priti S Hegde, Daniel S Chen, Ian Krop. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr PD1-6." @default.
• W4242969382 created "2022-05-12" @default.
• W4242969382 creator A5003642180 @default.
• W4242969382 creator A5009078484 @default.
• W4242969382 creator A5012487596 @default.
• W4242969382 creator A5015761216 @default.
• W4242969382 creator A5027371764 @default.
• W4242969382 creator A5028020706 @default.
• W4242969382 creator A5032785430 @default.
• W4242969382 creator A5038215538 @default.
• W4242969382 creator A5045982804 @default.
• W4242969382 creator A5086309026 @default.
• W4242969382 creator A5087092015 @default.
• W4242969382 date "2015-05-01" @default.
• W4242969382 modified "2023-10-17" @default.
• W4242969382 title "Abstract PD1-6: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer" @default.
• W4242969382 doi "https://doi.org/10.1158/1538-7445.sabcs14-pd1-6" @default.
• W4242969382 hasPublicationYear "2015" @default.
• W4242969382 type Work @default.
• W4242969382 citedByCount "23" @default.
• W4242969382 countsByYear W42429693822015 @default.
• W4242969382 countsByYear W42429693822016 @default.
• W4242969382 countsByYear W42429693822017 @default.
• W4242969382 countsByYear W42429693822018 @default.
• W4242969382 countsByYear W42429693822019 @default.
• W4242969382 countsByYear W42429693822020 @default.
• W4242969382 countsByYear W42429693822021 @default.
• W4242969382 crossrefType "journal-article" @default.
• W4242969382 hasAuthorship W4242969382A5003642180 @default.
• W4242969382 hasAuthorship W4242969382A5009078484 @default.
• W4242969382 hasAuthorship W4242969382A5012487596 @default.
• W4242969382 hasAuthorship W4242969382A5015761216 @default.
• W4242969382 hasAuthorship W4242969382A5027371764 @default.
• W4242969382 hasAuthorship W4242969382A5028020706 @default.
• W4242969382 hasAuthorship W4242969382A5032785430 @default.
• W4242969382 hasAuthorship W4242969382A5038215538 @default.
• W4242969382 hasAuthorship W4242969382A5045982804 @default.
• W4242969382 hasAuthorship W4242969382A5086309026 @default.
• W4242969382 hasAuthorship W4242969382A5087092015 @default.
• W4242969382 hasConcept C121608353 @default.
• W4242969382 hasConcept C126322002 @default.
• W4242969382 hasConcept C143998085 @default.
• W4242969382 hasConcept C197934379 @default.
• W4242969382 hasConcept C2775930923 @default.
• W4242969382 hasConcept C2776694085 @default.
• W4242969382 hasConcept C2776802502 @default.
• W4242969382 hasConcept C2777511904 @default.
• W4242969382 hasConcept C2778822529 @default.
• W4242969382 hasConcept C2779984678 @default.
• W4242969382 hasConcept C2780110267 @default.
• W4242969382 hasConcept C530470458 @default.
• W4242969382 hasConcept C71924100 @default.
• W4242969382 hasConceptScore W4242969382C121608353 @default.
• W4242969382 hasConceptScore W4242969382C126322002 @default.
• W4242969382 hasConceptScore W4242969382C143998085 @default.
• W4242969382 hasConceptScore W4242969382C197934379 @default.
• W4242969382 hasConceptScore W4242969382C2775930923 @default.
• W4242969382 hasConceptScore W4242969382C2776694085 @default.
• W4242969382 hasConceptScore W4242969382C2776802502 @default.
• W4242969382 hasConceptScore W4242969382C2777511904 @default.
• W4242969382 hasConceptScore W4242969382C2778822529 @default.
• W4242969382 hasConceptScore W4242969382C2779984678 @default.
• W4242969382 hasConceptScore W4242969382C2780110267 @default.
• W4242969382 hasConceptScore W4242969382C530470458 @default.
• W4242969382 hasConceptScore W4242969382C71924100 @default.
• W4242969382 hasIssue "9_Supplement" @default.
• W4242969382 hasLocation W42429693821 @default.
• W4242969382 hasOpenAccess W4242969382 @default.
• W4242969382 hasPrimaryLocation W42429693821 @default.
• W4242969382 hasRelatedWork W181195935 @default.
• W4242969382 hasRelatedWork W2020150632 @default.
• W4242969382 hasRelatedWork W2109800555 @default.
• W4242969382 hasRelatedWork W2331329572 @default.
• W4242969382 hasRelatedWork W2388022328 @default.
• W4242969382 hasRelatedWork W2591616149 @default.
• W4242969382 hasRelatedWork W2783325361 @default.
• W4242969382 hasRelatedWork W3033574736 @default.
• W4242969382 hasRelatedWork W3177425057 @default.
• W4242969382 hasRelatedWork W4311544009 @default.
• W4242969382 hasVolume "75" @default.
• W4242969382 isParatext "false" @default.
• W4242969382 isRetracted "false" @default.
• W4242969382 workType "article" @default.